The impact statement in SWOG's network operations grant application succinctly summarizes our work and our goals: By continuously improving inclusion, engagement, and scientific innovation, SWOG will enhance cancer clinical trial development and conduct, reducing the burden of human neoplasm. The SWOG National Clinical Trials Network Group has established itself as an innovative, collaborative, a n d cost-effective NCTN constituent. SWOG has 60 years of trial experience, and its work has led to the Food and Drug Administration approval of 14 regimens, changing and informing oncologic practice hundreds of time more. In our 2013 grant application, we promised to make unique contributions to the new NCTN enterprise, and we successfully did so over the last five years. We are strongly committed to furthering our efforts over the next six. SWOG designs and directs high-value, pathway- and immune- driven oncology research, with the goal of achieving practice-changing results that are meaningful to both persons affected by cancer and investigators. The group's current network includes more than 1,000 member sites, with 5,000 physicians who practice across the United States, Canada, South Korea, Mexico, Saudi Arabia, and South America. Twenty-three NCI-designated cancer centers number among our members, as do 22 Specialized Programs in Oncology Research Excellence. From early 2014 through mid-2017, SWOG investigators published more than 188 cancer treatment articles and abstracts, and enrolled 12,819 patients into NCTN therapeutic trials. SWOG actively collaborates in NCTN direct research and administrative functions and has developed training and education tools used throughout the network. SWOG's mission is to significantly improve lives through cancer clinical trials and translational research. The following guiding principles, ratified in 9/2017, are the foundation upon which we build to achieve that end: ? We make patients our absolute highest priority ? We ensure that the best science drives our research ? We embrace and encourage diversity in leadership and membership, to effectively solve problems in cancer ? We demand integrity, accountability, and ethical behavior in SWOG ? We foster and mentor young investigators, to ensure excellent clinical research for future generations Over the next grant cycle, we will provide an efficient, innovative, and nimble network capable of developing and conducting abroad framework of clinical and translational trials; we will meaningfully contribute to the NCTN; and we will help patients lead longer and meaningful lives. SWOG will remain an innovative force in the design of the next generation of oncologic therapies.
SWOG?s clinical and translational research will lead to a better understanding of the biology underlying neoplastic disease and will ultimately enable those potentially affected by cancer to lead longer, healthier lives.
|Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888|
|Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095|
|Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528|
|Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153|
|Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428|
|Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660|
|Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120|
|Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707|
|Unger, Joseph M; Vaidya, Riha; Gore, John L (2018) Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urol Oncol :|
|Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742|
Showing the most recent 10 out of 249 publications